[HTML][HTML] The therapeutic potential of nanobodies

I Jovčevska, S Muyldermans - BioDrugs, 2020 - Springer
Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …

ImmunoPET: concept, design, and applications

W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Applications of nanobodies

S Muyldermans - Annual review of animal biosciences, 2021 - annualreviews.org
Unique, functional, homodimeric heavy chain–only antibodies, devoid of light chains, are
circulating in the blood of Camelidae. These antibodies recognize their cognate antigen via …

[HTML][HTML] Nanobodies: a review of generation, diagnostics and therapeutics

B Jin, S Odongo, M Radwanska, S Magez - International journal of …, 2023 - mdpi.com
Nanobodies, also referred to as single domain-based VHHs, are antibody fragments derived
from heavy-chain only IgG antibodies found in the Camelidae family. Due to their small size …

Nanobodies as therapeutics: big opportunities for small antibodies

S Steeland, RE Vandenbroucke, C Libert - Drug discovery today, 2016 - Elsevier
Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

[HTML][HTML] Immunogenicity risk profile of nanobodies

C Ackaert, N Smiejkowska, C Xavier… - Frontiers in …, 2021 - frontiersin.org
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …

[HTML][HTML] Nanobody: a promising toolkit for molecular imaging and disease therapy

G Bao, M Tang, J Zhao, X Zhu - EJNMMI research, 2021 - Springer
Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with
many unique properties such as small size, excellent solubility, superior stability, quick …

Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma

M Keyaerts, C Xavier, J Heemskerk… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor
characteristics in breast cancer to guide therapy. Anti-HER2 treatment has clear survival …

[PDF][PDF] Nanobody—A versatile tool for cancer diagnosis and therapeutics

M Liu, L Li, D Jin, Y Liu - Wiley Interdisciplinary Reviews …, 2021 - researchgate.net
In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment,
their applications are still hampered in therapeutic development due to limitations, such as …

[HTML][HTML] HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and …

B Altunay, A Morgenroth, M Beheshti, A Vogg… - European journal of …, 2021 - Springer
Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies
and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including …